Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short - CNBC
- Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short CNBC
- Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations Yahoo Finance
- Updated: Lilly’s shares tank after trimming revenue guidance. It also cut three assets Endpoints News
- Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products Investors | Eli Lilly and Company